| Title |
Author |
Type |
Date |
Words |
| Research and Markets: Therapeutic Proteins: Strategies to Modulate Their Plasma Half-lives. |
|
|
May 29, 2012 |
530 |
| Presentation Highlights Clinical Potential of Navidea Biopharmaceuticals' -Amyloid Imaging Biomarker AZD4694. |
|
|
May 29, 2012 |
953 |
| Research and Markets: Chitosan-Based Systems for Biopharmaceuticals: Delivery, Targeting and Polymer Therapeutics. |
|
|
May 22, 2012 |
365 |
| Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation. |
|
|
May 22, 2012 |
429 |
| Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex(TM) (ferric citrate) at the 49th ERA-EDTA Congress. |
|
|
May 21, 2012 |
720 |
| iPierian Advances Monoclonal Antibody Drug Development Programs Targeting Tau Protein and the Complement System for the Treatment of Neurodegenerative Diseases. |
|
|
May 21, 2012 |
785 |
| Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex(TM) (ferric citrate) at the 49th ERA-EDTA Congress. |
|
|
May 21, 2012 |
728 |
| KYTHERA Biopharmaceuticals Files Registration Statement for Proposed Initial Public Offering. |
|
|
May 17, 2012 |
421 |
| Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial. |
|
|
May 16, 2012 |
1719 |
| Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A. |
|
|
May 15, 2012 |
584 |
| Keryx Biopharmaceuticals Announces Upcoming Poster Presentations of Zerenex(TM) (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings. |
|
|
May 9, 2012 |
706 |
| SK Biopharmaceuticals Enters into a Licensing Agreement with Hanmi Pharmaceutical. |
|
Company overview |
May 9, 2012 |
797 |
| Sutro Closes $16.5 Million Second Tranche of Series C Financing. |
|
|
May 8, 2012 |
468 |
| Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403. |
|
|
May 7, 2012 |
606 |
| Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris. |
|
|
May 7, 2012 |
501 |
| KYTHERA Biopharmaceuticals Announces Presentation of Positive Results from First of Two ATX-101 European Phase III Trials for Reduction of Submental Fat. |
|
Clinical report |
May 7, 2012 |
1248 |
| Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia[TM]. |
|
Clinical report |
May 4, 2012 |
894 |
| Integral Molecular Announces Patent Allowance for its Membrane Protein Lipoparticle Technology. |
|
|
May 3, 2012 |
355 |
| Alder BioPharmaceuticals Closes $38 Million Series D Financing. |
|
|
May 1, 2012 |
745 |
| KYTHERA Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat. |
|
|
Apr 25, 2012 |
1073 |
| Navidea Biopharmaceuticals Announces Participation in Alzheimer's Disease Scientific Meetings. |
|
|
Apr 25, 2012 |
542 |
| Integral Molecular Announces Lipoparticle Distribution in Japan by Funakoshi. |
|
|
Apr 25, 2012 |
442 |
| Dr. Mary Haak-Frendscho, Chairperson of Compugen's US Subsidiary, to Give Keynote Address at China Pharmaceutical R&D Summit. |
|
|
Apr 23, 2012 |
601 |
| Law Firm Brower Piven Announces Investigation in Connection With the Acquisition of Ardea Biosciences, Inc. by AstraZeneca Biopharmaceuticals Inc. |
|
|
Apr 23, 2012 |
269 |
| Adimab Announces New Antibody Discovery Program with Gilead and Initiates First Bispecific Antibody Collaboration. |
|
|
Apr 19, 2012 |
625 |
| Orphan Drug Designation Granted to SK Biopharmaceuticals' Carisbamate for the Management of Infantile Spasms. |
|
|
Apr 19, 2012 |
1392 |
| Ipsen's Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B. |
|
|
Apr 17, 2012 |
1285 |
| Research and Markets: Nabi Biopharmaceuticals - Strategy and SWOT Report. |
|
Company overview |
Apr 10, 2012 |
413 |
| Navidea Biopharmaceuticals Presents Favorable Comparison of Lymphoseek[R] to Sulfur Colloid at Sentinel Node Oncology Foundation and Sentinel Lymph Node Working Group. |
|
|
Apr 3, 2012 |
1322 |
| Therapeutic Antibody Producing Cells Encapsulated Using Cell-in-a-Box[R] Encapsulation Technology Proven Effective for Targeted Treatment of Various Diseases. |
|
|
Apr 3, 2012 |
735 |
| PolyTherics and Spirogen Announce a Research Collaboration to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer. |
|
|
Apr 2, 2012 |
895 |
| Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. |
|
Brief article |
Apr 1, 2012 |
216 |
| Navidea Biopharmaceuticals to Present at the 11th Annual Needham Healthcare Conference. |
|
Conference news |
Mar 29, 2012 |
257 |
| Navidea Biopharmaceuticals Announces Presentation of Lymphoseek[R] Phase 3 Data at Society of Surgical Oncology Meeting. |
|
Clinical report |
Mar 28, 2012 |
1406 |
| Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates. |
|
|
Mar 28, 2012 |
1429 |
| Asterand's Subsidiary BioSeek Extends Collaboration with Merck Serono. |
|
|
Mar 28, 2012 |
427 |
| Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs. |
|
|
Mar 26, 2012 |
1257 |
| SK Biopharmaceuticals to Initiate Phase 2 Trials in US. |
|
Company overview |
Mar 16, 2012 |
933 |
| BiovaxID[R] Personalized Lymphoma Vaccine is Featured in Article Published in Drug Discovery News. |
|
|
Mar 15, 2012 |
988 |
| KYTHERA Biopharmaceuticals Announces Initiation of Pivotal U.S. Phase III Clinical Trials to Evaluate ATX-101 for Reduction of Submental Fat. |
|
|
Mar 5, 2012 |
1166 |
| SK Biopharmaceuticals Drug Program Wins Funding Support from Korean Government. |
|
Company overview |
Mar 2, 2012 |
766 |
| How are we doing and what's left to do? |
|
|
Mar 1, 2012 |
2162 |
| Courtagen to Partner with Avaxia Biologics in GI Acute Radiation Syndrome Initiative. |
|
|
Feb 29, 2012 |
650 |
| Compugen Presents Prediction Based Discovery Strategy at "Targets and Strategies for Drug Discovery" Conference. |
|
Conference news |
Feb 27, 2012 |
1268 |
| Angiochem Forms Collaboration with GlaxoSmithKline to Discover and Develop Treatments of Lysosomal Storage Diseases. |
|
|
Feb 27, 2012 |
657 |
| Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2011 Financial Results on Thursday, March 1, 2012. |
|
Financial report |
Feb 27, 2012 |
1078 |
| SK Biopharmaceuticals to Initiate Phase 2 Trials in US. |
|
|
Feb 22, 2012 |
521 |
| Biovest to Present on BiovaxID[R] Personalized Lymphoma Vaccine at San Francisco Cancer Biologics Conference. |
|
Conference news |
Feb 16, 2012 |
790 |
| Tanshinone I increases CYP1A2 protein expression and enzyme activity in primary rat hepatocytes. |
Lee, Wayne Y.M.; Zhou, Xuelin Or, Penelope M.Y.; Kwan, Yiu Wa; Yeung, John H.K.. |
Report |
Feb 15, 2012 |
7475 |
| Navidea President, Dr. Mark Pykett, to Participate in Panel Discussion on Companion Diagnostics at BIO CEO. |
|
|
Feb 13, 2012 |
538 |
| ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENT. |
|
|
Feb 8, 2012 |
802 |
| The Myelin Repair Foundation and ENDECE Neural Form Collaboration to Develop Myelin Regenerative Compounds for Multiple Sclerosis (MS) Treatment. |
|
Clinical report |
Feb 8, 2012 |
649 |
| The Myelin Repair Foundation and ENDECE Neural Form Collaboration to Develop Myelin Regenerative Compounds for Multiple Sclerosis (MS) Treatment. |
|
Clinical report |
Feb 8, 2012 |
682 |
| Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference. |
|
Conference news |
Feb 8, 2012 |
419 |
| Iran Starts Mass-Production of Antibody Medicines. |
|
|
Feb 6, 2012 |
219 |
| CytoDyn Presenting Update on Its Therapeutic Antibody Programs at the Therapeutic Potential of Antibodies for HIV Meeting in Boston, MA. |
|
|
Jan 13, 2012 |
1099 |
| Biovest Collaborates with Max Planck Institute to Advance its Hollow Fiber Bioreactors for the Manufacture of Viral Vaccines. |
|
|
Jan 12, 2012 |
977 |
| Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab. |
|
|
Jan 9, 2012 |
795 |
| Navidea Biopharmaceuticals Announces Panel Participation at the Biotech Showcase Conference. |
|
Conference news |
Jan 9, 2012 |
403 |
| SILENCE THERAPEUTICS PLC - Research and Development Collaboration Update. |
|
|
Jan 6, 2012 |
1083 |
| Neoprobe Corporation Becomes Navidea Biopharmaceuticals. |
|
|
Jan 5, 2012 |
272 |
| Navidea Biopharmaceuticals to Present at the Biotech Showcase Conference. |
|
Conference news |
Jan 5, 2012 |
414 |
| KYTHERA Biopharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference. |
|
Conference news |
Jan 3, 2012 |
163 |
| Amarantus BioSciences Updates Shareholders on Execution of Expanded Corporate Strategy. |
|
|
Jan 3, 2012 |
702 |
| The importance of [CO.sub.2] control during the manufacture of biopharmaceuticals: Kurt Hiltbrunner, market segment specialist at Mettler-Toledo process analytics, talks to pharma about [CO.sub.2] monitoring and control. |
|
Interview |
Jan 1, 2012 |
750 |
| The importance of [CO.sub.2] control during the manufacture of biopharmaceuticals: Kurt Hiltbrunner, market segment specialist at mettler-toledo process analytics, talks to pharma about [CO.sub.2] monitoring and control. |
|
Interview |
Jan 1, 2012 |
747 |
| Provenance Biopharmaceuticals Corp. Announces $8M Financing. |
|
|
Dec 31, 2011 |
309 |
| Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement. |
|
|
Dec 22, 2011 |
409 |
| Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts. |
|
|
Dec 22, 2011 |
1054 |
| Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics. |
|
|
Dec 21, 2011 |
387 |
| Nuvilex Associate Expands Ownership of Patents to Include Production of Therapeutic Antibodies. |
|
|
Dec 20, 2011 |
589 |
| Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars. |
|
|
Dec 19, 2011 |
1687 |
| Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars. |
|
|
Dec 19, 2011 |
1699 |
| ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012. |
|
|
Dec 15, 2011 |
421 |
| GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals. |
|
|
Dec 14, 2011 |
956 |
| KYTHERA Biopharmaceuticals Receives Notice of Allowance for Additional U.S. Patent on ATX-101 (Formulations of Deoxycholic Acid and Salts). |
|
|
Dec 14, 2011 |
642 |
| BiovaxID[R] Lymphoma Vaccine-Induced T-Cell Immune Responses Complement Rituximab Induction Chemotherapy and Significantly Correlate with Overall Survival in Mantle Cell Lymphoma. |
|
|
Dec 13, 2011 |
1319 |
| Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH). |
|
|
Dec 12, 2011 |
1422 |
| Bruker Announces Partnership with GRAST at Chungnam National University in Korea to Develop Glycomics Reference Site. |
|
|
Dec 1, 2011 |
655 |
| Amarantus BioSciences Receives Grant from Brewer Sports International for Traumatic Brain Injury. |
|
|
Nov 30, 2011 |
900 |
| Ipsen's partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors. |
|
|
Nov 28, 2011 |
1297 |
| Research and Markets: Triple Analysis: Leukemia, Cancer Vaccines and Antibodies. |
|
|
Nov 28, 2011 |
342 |
| BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility. |
|
|
Nov 28, 2011 |
1275 |
| Research and Markets: Apoptosis, Antibodies and Peptides: Cancer Drug Development Strategies. |
|
|
Nov 24, 2011 |
538 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Cancer Vaccines and Antibodies. |
|
|
Nov 23, 2011 |
449 |
| Amarantus Biosciences and Banyan Biomarkers Announce Traumatic Brain Injury Research Collaboration. |
|
|
Nov 22, 2011 |
816 |
| Keryx Biopharmaceuticals Announces Highlights from Zerenex(TM) (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting. |
|
|
Nov 14, 2011 |
1092 |
| Keryx Biopharmaceuticals Announces Highlights from Zerenex(TM) (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting. |
|
|
Nov 14, 2011 |
1094 |
| Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference. |
|
Conference news |
Nov 11, 2011 |
394 |
| Health Robotics' Oncology Focus: Revolutionary i.v.STATION's Monoclonal Antibody Therapy Project at St-Antonius Hospital. |
|
|
Nov 9, 2011 |
908 |
| Research and Markets: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. |
|
|
Nov 9, 2011 |
433 |
| Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex(TM) (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting. |
|
|
Nov 9, 2011 |
844 |
| KYTHERA Biopharmaceuticals Presents Long-Term Follow-up Study Results From Phase 2 Trials With ATX-101. |
|
|
Nov 7, 2011 |
1142 |
| Accentia Biopharmaceuticals Announces Series of Agreements as Part of Debt Reduction Strategy to Strengthen Financial Condition, Improve Balance Sheet and Support Advancement of Immunotherapy Pipeline. |
|
|
Nov 7, 2011 |
899 |
| NanoSmart(TM) Pharmaceuticals Joins Forces with Children's Hospital Los Angeles to Fight Pediatric Cancer. |
|
|
Nov 1, 2011 |
504 |
| Mentor Capital Adds to European Cancer Portfolio with AGI Biopharmaceuticals Melanoma Vaccine. |
|
|
Oct 31, 2011 |
286 |
| Pall Kicks Off Educational Series on Single-Use Biopharm Manufacturing Practices. |
|
Company overview |
Oct 28, 2011 |
808 |
| Sanofi Pasteur Presents New Data Confirming Fluzone High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population. |
|
|
Oct 21, 2011 |
1840 |
| Xencor Initiates Phase 1 Study of XmAb5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases. |
|
|
Oct 21, 2011 |
561 |
| EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia. |
|
|
Oct 19, 2011 |
437 |
| Research and Markets: Global Biopharmaceuticals Industry Report - profiling and comparing the top 200 companies. |
|
Report |
Oct 19, 2011 |
423 |
| SK biopharmaceuticals Enters into a Licensing Agreement with Premier Chinese Biopharmaceutical Company. |
|
|
Oct 19, 2011 |
529 |
| Research and Markets: Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies. |
|
|
Oct 17, 2011 |
415 |
| Update on Development of Factor VIII Biopump. |
|
|
Oct 14, 2011 |
704 |
| Research and Markets: Lung Cancer Therapeutic Antibodies: 2011 Pipeline, Strategies and Clinical Report. |
|
Clinical report |
Oct 10, 2011 |
659 |
| Research and Markets: Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical. |
|
|
Oct 7, 2011 |
503 |
| Ipsen's Partner, Inspiration Biopharmaceuticals, Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B. |
|
|
Oct 3, 2011 |
1306 |
| Analytical Tool - Cancer Therapeutic Antibodies. |
|
|
Oct 3, 2011 |
668 |
| Accentia Biopharmaceuticals Joins National Organization for Rare Disorders (NORD) Corporate Council. |
|
|
Sep 20, 2011 |
1010 |
| CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001. |
|
|
Sep 20, 2011 |
751 |
| CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001. |
|
|
Sep 20, 2011 |
753 |
| KYTHERA Biopharmaceuticals Announces $37.4M Financing. |
|
|
Sep 19, 2011 |
584 |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex(TM) (Ferric Citrate) Phase 3 Long-Term Study. |
|
|
Sep 19, 2011 |
1211 |
| Biovest and NHRC to Continue Collaboration with Shared Resources to Extend the Potential of Hollow Fiber Bioreactor Technology for Pandemic Influenza Virus. |
|
|
Sep 19, 2011 |
1021 |
| Mayo Clinic Enters Collaboration That Takes Aim at Lou Gehrig's Disease. |
|
|
Sep 19, 2011 |
514 |
| SK biopharmaceuticals Enters into a Collaboration Agreement to Study Lou Gehrig's Disease. |
|
|
Sep 19, 2011 |
736 |
| ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development. |
|
|
Sep 15, 2011 |
1034 |
| Teva Announces Drug Development Investment in Cocrystal Discovery Inc. for Novel Antiviral Therapeutics. |
|
|
Sep 15, 2011 |
1164 |
| Accentia Biopharmaceuticals Announces that FDA Grants Orphan Drug Status for Revimmune[TM] Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant. |
|
|
Sep 14, 2011 |
1280 |
| Research and Markets: Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market. |
|
|
Sep 13, 2011 |
535 |
| Theraclone Sciences Secures $10.6 Million in Series B Extension Financing. |
|
|
Sep 8, 2011 |
327 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations. |
|
|
Sep 6, 2011 |
417 |
| Therapeutic Proteins Market Dominated by Roche, Amgen and Novo Nordisk: companiesandmarkets.com. |
|
|
Sep 6, 2011 |
446 |
| AnaptysBio Successfully Generates Therapeutic Antibodies in Partnership with a Leading Global Pharma. |
|
|
Sep 1, 2011 |
374 |
| Keryx Biopharmaceuticals Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer. |
|
|
Aug 31, 2011 |
1015 |
| Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration's Hemophilia Pipeline in Europe. |
|
|
Aug 30, 2011 |
1819 |
| Abbott Japan and Eisai Announce Launch of Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R). |
|
|
Aug 30, 2011 |
621 |
| Zymeworks Inc. Announces Collaboration with Merck to Develop Bi-specific Antibody Therapeutics. |
|
|
Aug 29, 2011 |
528 |
| 4-Antibody AG Forms Collaboration with Human Genome Sciences. |
|
|
Aug 16, 2011 |
500 |
| Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress. |
|
|
Jul 28, 2011 |
1310 |
| Ipsen's partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23rd ISTH congress. |
|
|
Jul 28, 2011 |
1540 |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study. |
|
|
Jul 27, 2011 |
1363 |
| Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions. |
|
|
Jul 11, 2011 |
593 |
| PROLOR Biotech Receives New U.S. Patent Allowance Covering Broad Applications of Its CTP Platform for Long Acting Therapeutic Proteins. |
|
|
Jul 11, 2011 |
1189 |
| Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen. |
|
|
Jul 11, 2011 |
1004 |
| OSO BioPharmaceuticals Receives DEA Approval to Handle Controlled Substances. |
|
|
Jun 24, 2011 |
272 |
| Accentia Biopharmaceuticals Announces that FDA grants Orphan Drug Status for Revimmune[TM] Therapy for the Treatment of Two Autoimmune Diseases: Systemic Sclerosis & Hemolytic Anemia. |
|
|
Jun 23, 2011 |
1085 |
| Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences. |
|
Conference news |
Jun 22, 2011 |
521 |
| Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6. |
|
|
Jun 20, 2011 |
433 |
| aTyr Pharma Honored with Red Herring 100 North America Award for Discovering and Developing Innovative Medicines Based on Physiocrine Biology. |
|
|
Jun 17, 2011 |
569 |
| Accentia Biopharmaceuticals Announces Financing to Advance Revimmune[TM] to Treat Autoimmune Disease including Multiple Sclerosis. |
|
|
Jun 14, 2011 |
1114 |
| Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma. |
|
|
Jun 6, 2011 |
821 |
| Keryx Biopharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference. |
|
Conference news |
Jun 6, 2011 |
425 |
| Data on Neogenix Oncology's Phase I Study of Novel Therapeutic Antibody NPC-1C (Ensituximab) to be Presented at ASCO's 2011 Annual Meeting. |
|
|
Jun 3, 2011 |
660 |
| ImmunoCellular Therapeutics and BioWa Announce License for the Research and Development of Therapeutic Antibodies in Cancer. |
|
|
Jun 2, 2011 |
676 |
| Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics. |
|
|
Jun 2, 2011 |
681 |
| Accentia Biopharmaceuticals Announces Key Additions to its Scientific Advisory Board to Advance Revimmune[TM] for the Treatment of Autoimmune Diseases including Multiple Sclerosis. |
|
|
Jun 2, 2011 |
1260 |
| Scientists using plants to produce therapeutic antibodies. |
|
Clinical report |
May 27, 2011 |
247 |
| Xcellerex[R] and Gallus BioPharmaceuticals Announce Biomanufacturing Collaboration. |
|
|
May 24, 2011 |
968 |
| Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo. |
|
Conference news |
May 23, 2011 |
900 |
| Study Shows Sutro Biopharma's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals. |
|
|
May 19, 2011 |
577 |
| Ridgemont Equity Partners Acquires Majority Interest in Gallus BioPharmaceuticals. |
|
|
May 18, 2011 |
691 |
| Goodwin Biotechnology and RAFAGEN Announce a Collaboration. |
|
|
May 17, 2011 |
506 |
| ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche. |
|
|
May 16, 2011 |
1122 |
| ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche. |
|
|
May 16, 2011 |
1129 |
| BioInvent and ThromboGenics Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche. |
|
|
May 16, 2011 |
959 |
| OSO BioPharmaceuticals Manufacturing LLC Honored for Corporate Efforts to Protect Integrity of Rio Grande. |
|
|
May 13, 2011 |
275 |
| Research and Markets: Six Pharmaceuticals Report Bundle - In-Depth Reports Available at a 15% Discount. |
|
Report |
May 12, 2011 |
1015 |
| Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology(TM). |
|
|
May 10, 2011 |
419 |
| Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology(TM). |
|
|
May 10, 2011 |
461 |
| Research and Markets: Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects. |
|
|
May 5, 2011 |
550 |
| Accentia Biopharmaceuticals Announces that Revimmune[TM] Autoimmune Disease Therapy is Featured in Peer-review Journal. |
|
|
May 4, 2011 |
1010 |
| Rodman & Renshaw Acts as a Co-Manager to Keryx Biopharmaceuticals, Inc. in Common Stock Offering. |
|
|
May 4, 2011 |
780 |
| Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering. |
|
|
May 4, 2011 |
594 |
| Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex(TM) in Hyperphosphatemia. |
|
|
May 2, 2011 |
946 |
| Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex(TM) in Hyperphosphatemia. |
|
|
May 2, 2011 |
1102 |
| Compugen Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy. |
|
|
Apr 27, 2011 |
1211 |
| Proteostasis Therapeutics Licenses Novel Protein Clearance Targets, Compounds from Harvard University. |
|
|
Apr 26, 2011 |
774 |
| Dyax Corp. and Five Prime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies. |
|
|
Apr 26, 2011 |
1225 |
| Abbott Japan and Eisai Receive Approval to Market the Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancrelipase) in Japan. |
|
|
Apr 22, 2011 |
1014 |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical. |
|
|
Apr 18, 2011 |
786 |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical. |
|
|
Apr 18, 2011 |
942 |
| Inspiration Biopharmaceuticals Recognizes World Hemophilia Day - April 17 - and the Inspiring Voices within the Hemophilia Community. |
|
Company overview |
Apr 15, 2011 |
971 |
| Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. |
Salminen, Kaisa A.; Meyer, Achim; Jerabkova, Lenka; Korhonen, Laura E.; Rahnasto, Minna; Juvonen, Ri |
Report |
Apr 15, 2011 |
4961 |
| Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents. |
|
|
Apr 12, 2011 |
965 |
| Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer. |
|
|
Apr 6, 2011 |
897 |
| Keryx Biopharmaceuticals Announces Results on KRX-0401 (Perifosine) at American Association for Cancer Research Annual Meeting. |
|
Financial report |
Apr 5, 2011 |
1202 |
| Research and Markets: Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market. |
|
|
Apr 5, 2011 |
442 |
| Neogenix Oncology Novel Therapeutic Antibody, NEO-101 (Ensituximab) Data to Be Presented at AACR's 2011 Annual Symposium. |
|
|
Apr 1, 2011 |
710 |
| Research and Markets: Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline - 2011 Report. |
|
|
Mar 31, 2011 |
881 |
| Research and Markets: Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011. |
|
|
Mar 30, 2011 |
571 |
| Research and Markets: Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011. |
|
|
Mar 30, 2011 |
489 |
| XTL BIOPHARMACEUTICALS TO ACQUIRE MINOGUARD LTD. |
|
|
Mar 29, 2011 |
479 |
| KYTHERA Biopharmaceuticals Presents Patient Reported Outcomes from Phase IIB Study with ATX-101 Demonstrating Reduction of Submental Fat. |
|
Clinical report |
Mar 17, 2011 |
951 |
| Cytovance Biologics Secures a Staged $22.5 Million Equity Investment to Expand Its Biologic Manufacturing Capabilities in Oklahoma City. |
|
Company overview |
Mar 15, 2011 |
795 |
| Steven Hubert Joins Omnia Biologics. |
|
|
Mar 15, 2011 |
360 |
| Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease. |
|
|
Mar 8, 2011 |
1138 |
| Reportlinker Adds Drug Delivery in Cancer - Technologies, Markets and Companies. |
|
|
Mar 7, 2011 |
765 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations. |
|
|
Feb 28, 2011 |
615 |
| OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends and Best Practices at DCAT Week. |
|
|
Feb 24, 2011 |
307 |
| Enobia Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy. |
|
|
Feb 24, 2011 |
1009 |
| KYTHERA Biopharmaceuticals Presents Positive Data from Phase IIb Study with ATX-101 Demonstrating Reduction of Submental Fat. |
|
Clinical report |
Feb 22, 2011 |
1025 |
| Biologics may increase cardiovascular risk in psoriasis. |
Boschert, Sherry |
|
Feb 15, 2011 |
957 |
| RegeneRx Biopharmaceuticals To Present at the 13th Annual BIO CEO & Investor Conference on February 15th. |
|
Conference news |
Feb 14, 2011 |
961 |
| Cocaine vaccine looks promising: injections raise antibodies to limit drug's effects in mice. |
Seppa, Nathan |
|
Feb 12, 2011 |
484 |
| Anacor and Medicis Enter Into Research and Development Collaboration for the Treatment of Acne. |
|
|
Feb 10, 2011 |
1089 |
| Reportlinker Adds Analytical Tool - Cancer Therapeutic Antibodies. |
|
|
Feb 9, 2011 |
783 |
| KYTHERA Biopharmaceuticals Announces Positive Results from Phase IIb Study with ATX-101 Demonstrating Reduction of Submental Fat. |
|
Clinical report |
Feb 4, 2011 |
823 |
| Ipsen's Partner Inspiration Biopharmaceuticals Announces Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B. |
|
|
Feb 3, 2011 |
1271 |
| Reportlinker Adds Therapeutic Proteins to 2014. |
|
|
Feb 1, 2011 |
479 |
| Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers. |
|
|
Jan 25, 2011 |
661 |
| OSO BioPharmaceuticals Taps Craig Mastenbaum to Lead West Coast Business Development. |
|
|
Jan 21, 2011 |
260 |
| MediGene Exercises Option For Anti-L1 Monoclonal Antibody And Continues Collaboration With DKFZ (German Cancer Research Center). |
|
|
Jan 20, 2011 |
700 |
| Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration. |
|
|
Jan 19, 2011 |
658 |
| Data on Neogenix Oncology's Novel Therapeutic Antibody NPC-1C (Ensituximab) to be Presented at ASCO's 2011 Gastrointestinal Cancers Symposium. |
|
|
Jan 18, 2011 |
635 |
| Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy. |
|
|
Jan 10, 2011 |
977 |
| PPD Establishes Joint Venture for Drug Discovery of Large Molecules. |
|
|
Jan 10, 2011 |
852 |
| RegeneRx Biopharmaceuticals Receives $1.45 Million and Secures Additional $11 Million in Committed Funding. |
|
|
Jan 7, 2011 |
1609 |
| KYTHERA Biopharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference. |
|
Conference news |
Jan 6, 2011 |
293 |
| Spirogen Ltd. Announces a Research Collaboration and License Agreement With Genentech for the Discovery and Development of Antibody Drug Conjugates. |
|
|
Jan 6, 2011 |
451 |
| Biovest to Present at OneMedForum Conference. |
|
|
Jan 6, 2011 |
800 |
| Synageva BioPharma Corp and to-BBB to Collaborate on Brain Drug Delivery for Rare Diseases. |
|
|
Jan 5, 2011 |
510 |
| Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells. |
|
|
Jan 5, 2011 |
792 |
| Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors. |
|
|
Jan 4, 2011 |
539 |
| Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors. |
|
|
Jan 4, 2011 |
546 |
| Reportlinker Adds Competitor Analysis: Antibody Therapy of Inflammatory and Autoimmune Diseases. |
|
|
Dec 29, 2010 |
616 |
| BioInvent Extends Antibody Collaboration with Japanese Pharmaceutical Partner. |
|
|
Dec 21, 2010 |
531 |
| Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer. |
|
|
Dec 7, 2010 |
641 |
| Research and Markets: Triple Analysis: Cancer Vaccines, Antibodies and Peptides. |
|
|
Dec 6, 2010 |
610 |
| MarketsandMarkets: U.S. Biopharmaceuticals Market Worth $144 Billion by 2016. |
|
|
Dec 2, 2010 |
1034 |
| Keryx Biopharmaceuticals Announces Poster Presentations of KRX-0401 (Perifosine) at the 52nd Annual Meeting of the American Society of Hematology. |
|
|
Dec 2, 2010 |
976 |
| Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group(TM). |
|
|
Dec 1, 2010 |
835 |
| Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group(TM). |
|
|
Dec 1, 2010 |
897 |
| XOMA GETS $2.0 MIL PAYMENT UNDER ANTIBODY DISCOVERY. |
|
|
Dec 1, 2010 |
688 |
| Accentia Biopharmaceuticals Announces Strategic Agreement with Baxter. |
|
|
Nov 29, 2010 |
868 |
| f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic Antibodies. |
|
|
Nov 22, 2010 |
551 |
| Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A. |
|
|
Nov 19, 2010 |
1195 |
| Ipsen's Partner Inspiration Biopharmaceuticals Announces the Treatment of the First Patient in Phase III Pivotal Study of OBI-1 for Acquired Hemophilia A. |
|
|
Nov 19, 2010 |
1404 |
| Biopharmaceuticals Market to Reach More Than US$ 167 Billion by 2015. |
|
|
Nov 19, 2010 |
335 |
| Accentia Biopharmaceuticals Emerges from Chapter 11 Reorganization. |
|
|
Nov 17, 2010 |
882 |
| Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference. |
|
Conference news |
Nov 15, 2010 |
512 |
| Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo. |
|
|
Nov 15, 2010 |
1028 |
| Scientists Demystify Enzyme Responsible for Drug, Food Metabolism. |
|
|
Nov 13, 2010 |
471 |
| AnaptysBio Adds Dr. Jan de Vries, Dr. Nicholas Lydon and Dr. Phillip Patten to Advisory Boards. |
|
|
Nov 10, 2010 |
1111 |
| Research and Markets: Therapeutic Proteins to 2014. |
|
|
Nov 10, 2010 |
465 |
| Therapeutic Proteins to Reach $103 Billion by 2014, According to Greystone Research. |
|
|
Nov 9, 2010 |
393 |
| Fabrus Announces Conjugated Antibody Collaboration and New Phase of Growth. |
|
|
Nov 8, 2010 |
598 |
| Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology. |
|
Clinical report |
Nov 6, 2010 |
716 |
| Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP). |
|
|
Nov 5, 2010 |
812 |
| OPKO Invests in Novel Antibody Biotechnology Company. |
|
|
Nov 3, 2010 |
692 |
| Keryx Biopharmaceuticals to Present at Oppenheimer's 21st Annual Healthcare Conference. |
|
Conference news |
Oct 28, 2010 |
489 |
| Ablexis Forms Five-Member Pharmaceutical Consortium to Fund Technology Development. |
|
|
Oct 26, 2010 |
495 |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study. |
|
|
Oct 26, 2010 |
1576 |
| Morphotek[R], Inc. Awarded $2.5 Million from U.S. Department of Defense to Continue Development of Therapeutic Antibodies Against Microbial Bioweapons. |
|
|
Oct 21, 2010 |
757 |
| Research and Markets: Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. |
|
|
Oct 21, 2010 |
346 |
| Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference. |
|
Conference notes |
Oct 19, 2010 |
493 |
| Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe. |
|
|
Oct 19, 2010 |
855 |
| Charles River Announces Exclusive License with Transposagen Biopharmaceuticals, Inc. |
|
|
Oct 13, 2010 |
946 |
| ERYtech Pharma and Genzyme Corporation Sign Collaborative Research Agreement in Rare Diseases. |
|
|
Oct 12, 2010 |
474 |
| Micromet Announces FDA Acceptance of Investigational New Drug Application for BiTE Antibody MT111/MEDI-565. |
|
|
Oct 11, 2010 |
997 |
| Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile Antibody Therapy. |
|
|
Oct 6, 2010 |
1569 |
| Enhancing adherence through education. |
Smrtka, Jennifer; Caon, Christina; Saunders, Carol; Becker, Brenda L.; Baxter, Nancy |
Report |
Oct 1, 2010 |
8094 |
| Serum concentrations of antibodies against vaccine toxoids in children exposed perinatally to immunotoxicants. |
Heilmann, Carsten; Budtz-Jorgensen, Esben; Nielsen, Flemming; Heinzow, Birger; Weihe, Pal; Grandjean |
Report |
Oct 1, 2010 |
5959 |
| Neogenix Oncology to Commence Phase I Trial for Therapeutic Antibody for Pancreatic and Colorectal Cancer. |
|
|
Sep 29, 2010 |
592 |
| RECIPHARMCOBRA BIOLOGICS GRANTED PLASMID PATENT. |
|
|
Sep 29, 2010 |
781 |
| Keryx Biopharmaceuticals Initiates Long-Term Study Component of Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease on Dialysis. |
|
Report |
Sep 29, 2010 |
1716 |
| Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference. |
|
Conference news |
Sep 27, 2010 |
509 |
| KYTHERA Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference. |
|
Conference news |
Sep 20, 2010 |
264 |
| Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference. |
|
Conference news |
Sep 20, 2010 |
488 |
| Research and Markets: Aggregation of Therapeutic Proteins - Up-to-Date Resource on Protein Aggregation and its Consequences. |
|
|
Sep 16, 2010 |
402 |
| FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15. |
|
|
Sep 15, 2010 |
734 |
| Excelimmune Presents Preclinical Data at ICAAC Demonstrating that Human Recombinant Polyclonal Antibody Therapy Provides Protection Against MRSA. |
|
|
Sep 13, 2010 |
715 |
| Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein. |
|
|
Sep 9, 2010 |
561 |
| Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein. |
|
|
Sep 9, 2010 |
548 |
| Enobia Provides Update on Progress With ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia. |
|
|
Sep 8, 2010 |
844 |
| Research and Markets: Prostate Cancer: Vaccines and Therapeutic Antibodies - 2010. |
|
|
Sep 7, 2010 |
485 |
| Research and Markets: Breast Cancer: Vaccines and Therapeutic Antibodies - Findings on More than 30 Candidate Therapies, Including 22 Vaccines and 11 Antibodies. |
|
|
Sep 7, 2010 |
467 |
| Research and Markets: Alzheimers Disease Immunotherapy Pipeline: Vaccines, Therapeutic Antibodies and Emerging Strategies - 2010. |
|
|
Sep 6, 2010 |
806 |
| XOMA GETS $750,000 MILESTONE PAYMENT FROM AVEO PHARMACEUTICALS. |
|
|
Aug 28, 2010 |
451 |
| LFB's Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in the USA for Chronic Lymphocytic Leukemia. |
|
|
Aug 26, 2010 |
488 |
| Reportlinker Adds Analytical Tool - Cancer Therapeutic Antibodies. |
|
|
Aug 25, 2010 |
722 |
| CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility. |
|
|
Aug 24, 2010 |
501 |
| CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility. |
|
|
Aug 24, 2010 |
539 |
| CardioGenics Ships Biologics Beads to Merck. |
|
|
Aug 12, 2010 |
744 |
| Numerate and Intellikine Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha. |
|
|
Aug 11, 2010 |
543 |
| LifeSci Advisors Initiates Coverage on Keryx Biopharmaceuticals. |
|
|
Aug 2, 2010 |
906 |
| How and when to use biologics in Psoriasis. |
Kircik, Leon H.; Gonzalez, Mercedes E. |
Clinical report |
Aug 1, 2010 |
9882 |
| The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. |
Mrozikiewicz, P.M.; Bogacz, A.; Karasiewicz, M.; Mikolajczak, P.L.; Ozarowski, M.; Seremak-Mrozikiew |
|
Aug 1, 2010 |
4001 |
| Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins. |
|
|
Jul 27, 2010 |
415 |
| United States : XOMA Receives $750000 Milestone Payment From AVEO Pharmaceuticals. |
|
|
Jul 26, 2010 |
134 |
| Research and Markets: Omrix Biopharmaceuticals, Inc. - SWOT Framework Analysis - 2010. |
|
|
Jul 21, 2010 |
394 |
| Epizyme Scientists Detail Epigenetic Approaches to Cancer Therapy in Drug Discovery Today: Therapeutic Strategies and Current Opinion in Chemical Biology. |
|
|
Jul 16, 2010 |
486 |
| Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration. |
|
|
Jul 14, 2010 |
708 |
| Keryx Biopharmaceuticals Receives Orphan Drug Designation for KRX-0401 (Perifosine) for the Treatment of Neuroblastoma. |
|
|
Jul 14, 2010 |
1221 |
| AIDS vaccine eyed from HIV antibodies. |
|
|
Jul 8, 2010 |
199 |
| Western States Biopharmaceuticals and University of Colorado Announce Exclusive Licensing Agreement for TCISM(TM) Targets to Treat Autoimmune Diseases. |
|
|
Jul 8, 2010 |
740 |
| Powerful HIV antibodies found for vaccine. |
|
|
Jul 8, 2010 |
353 |
| Eiger BioPharmaceuticals Announces New HCV Synergy Data. |
|
|
Jul 1, 2010 |
486 |
| Eiger BioPharmaceuticals Announces New HCV Synergy Data. |
|
|
Jul 1, 2010 |
489 |
| Inhibition of cytochrome P450 3A4 activity by schisandrol A and gomisin A isolated from Fructus Schisandrae chinensis. |
Wan, C.-K.; Tse, A.K.; Yu, Z.-L.; Zhu, G.-Y.; Wang, H.; Fong, D.W.F. |
Report |
Jul 1, 2010 |
1922 |
| Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the Upcoming 12th World Congress on Gastrointestinal Cancer. |
|
Clinical report |
Jun 29, 2010 |
1043 |
| ImmunoGen, Inc. Earns Milestone with Start of SAR650984 Clinical Trial. |
|
|
Jun 24, 2010 |
599 |
| Research and Markets: Competitor Analysis: Streptococcal Vaccines and Antibodies. |
|
|
Jun 23, 2010 |
422 |
| Probactive Biotech, Inc. Announces an Agreement to Co-Develop Novel Biopharmaceuticals for Cancer with Dalat Nuclear Research Institute of Vietnam. |
|
|
Jun 22, 2010 |
511 |
| ENB-0040, a Bone Targeted Enzyme Replacement Therapy, Shows Promise in Children with Hypophosphatasia. |
|
|
Jun 21, 2010 |
770 |
| Morria Biopharmaceuticals Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress. |
|
Clinical report |
Jun 15, 2010 |
560 |
| Vatican, biotech firm invest $1 million on adult stem cells education. |
|
|
Jun 11, 2010 |
362 |
| Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma. |
|
|
Jun 7, 2010 |
1224 |
| Alder Biopharmaceuticals' ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer Patients. |
|
|
Jun 6, 2010 |
993 |
| Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress. |
|
Clinical report |
Jun 3, 2010 |
358 |
